

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049326 A1

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/4745 (2006.01)
A61K 31/4741 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/043684

(22) International Filing Date:

23 August 2024 (23.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/534,700 25 August 2023 (25.08.2023) US

(71) Applicant: **BIOCRIST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).


(72) Inventors: **KOTIAN, Pravin, L.**; 1139 Magnolia Run,
Hoover, AL 35226 (US). **BABU, Yarlagadda, S.**;
4836 Southlake Parkway, Birmingham, AL 35244 (US).
ZHANG, Weihe; 2645 Manchester Court, Vestavia Hills,

AL 35226 (US). **LIU, Yong**; 2733 Anna Steele Ln, Vestavia Hills, AL 35216 (US). **LV, Wei**; 5373 Park Side Circle, Hoover, AL 35244 (US). **JUAREZ, Luis**; 1700 Woodview Circle, Pelham, AL 35214 (US). **SPAULDING, Andrew, E.**; 1147 Riverchase Pkwy W, Hoover, Alabama 35244 (US). **DANG, Zhao**; 1226 Parliament Lane, Vestavia Hills, AL 35216 (US). **RAMAN, Krishnan**; 3739 Spearman Drive, Birmingham, AL 35216 (US).


(74) Agent: **GORDON, Dana, M.** et al.; FOLEY HOAG LLP,
155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5



FORMULAE (I)



FORMULAE (II)

(57) Abstract: Disclosed are tricyclic heteroaromatic compounds of formulae (I) and (II), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity activity, such as Netherton Syndrome. Formulae (I) and (II)

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*